ArticleSkeletal radiology2026
Percutaneous cryoablation of musculoskeletal tumours: the largest reported single-centre case series - outcomes, complications and subgroup analysis.
Article in Skeletal radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCryoablation is an image-guided, minimally invasive treatment technique that uses extreme cold to induce tumour destruction. Its role in musculoskeletal oncology has expanded in recent years, although large clinical series remain limited. This study reports a large single-centre experience of percutaneous cryoablation for musculoskeletal tumours, including metastatic lesions, benign and cartilaginous tumours, and primary bone tumours. MATERIALS AND
methodsThis was a single-centre retrospective cohort study conducted at a tertiary musculoskeletal oncology centre. All procedures were performed by a single specialist musculoskeletal interventional radiologist with over 20 years of experience. The study included patients who underwent percutaneous cryoablation for musculoskeletal tumours between June 2021 and December 2025. Clinical response, radiological response, recurrence, and complications were assessed over a median follow-up of 3 months (mean 8.7 months; range 0-48 months). Radiological response was assessed using pre-treatment and post-treatment Hounsfield Unit (HU) measurements on CT; this is not a validated radiological scoring system and is reported as a complementary, exploratory marker alongside standard clinical response assessment. Complications were graded using the CIRSE classification system.
resultsA total of 48 patients underwent percutaneous cryoablation during the study period. The cohort included 26 males and 22 females, with a median age of 40 years. A good or complete response was achieved in 28 patients, representing 58% of the total cohort. A partial response was achieved in seven patients, representing 15% of the total cohort. HU reduction was observed in 45 of 48 patients, representing 94% of the cohort. The overall complication rate was 6.3%, with three complications recorded among 48 procedures. No major complications or procedure-related deaths were observed.
conclusionsCryoablation appears to be a safe and effective minimally invasive treatment for selected musculoskeletal tumours. Most patients achieved a good, complete, or partial response, with a low complication rate. Hounsfield Unit reduction after treatment may provide a useful, though as yet non-validated, marker of radiological response. Further prospective studies with longer follow-up, standardised response criteria and validated complication grading are needed to confirm these findings.
Indexed as
Identifiers
42909541What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.